ATE459647T1 - Humane il-18 substitutionsmutanten und deren konjugate - Google Patents

Humane il-18 substitutionsmutanten und deren konjugate

Info

Publication number
ATE459647T1
ATE459647T1 AT04759472T AT04759472T ATE459647T1 AT E459647 T1 ATE459647 T1 AT E459647T1 AT 04759472 T AT04759472 T AT 04759472T AT 04759472 T AT04759472 T AT 04759472T AT E459647 T1 ATE459647 T1 AT E459647T1
Authority
AT
Austria
Prior art keywords
conjugates
human
substitution mutants
mutants
substitution
Prior art date
Application number
AT04759472T
Other languages
English (en)
Inventor
Narendra Bam
Jacab Bongers
Robert Kirkpatrick
Cheryl JANSON
Kyung Johanson
Zdenka Jonak
Xiayang Qiu
Ping-Yang Yeh
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE459647T1 publication Critical patent/ATE459647T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04759472T 2003-04-15 2004-04-13 Humane il-18 substitutionsmutanten und deren konjugate ATE459647T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46294703P 2003-04-15 2003-04-15
PCT/US2004/011309 WO2004091517A2 (en) 2003-04-15 2004-04-13 Conjugates comprising human il-18 and substitution mutants thereof

Publications (1)

Publication Number Publication Date
ATE459647T1 true ATE459647T1 (de) 2010-03-15

Family

ID=33300018

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759472T ATE459647T1 (de) 2003-04-15 2004-04-13 Humane il-18 substitutionsmutanten und deren konjugate

Country Status (9)

Country Link
US (2) US7311902B2 (de)
EP (2) EP1613274B1 (de)
JP (2) JP4753867B2 (de)
AR (1) AR044024A1 (de)
AT (1) ATE459647T1 (de)
DE (1) DE602004025799D1 (de)
ES (1) ES2340494T3 (de)
TW (1) TW200510454A (de)
WO (1) WO2004091517A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
US20100061958A1 (en) 2006-09-14 2010-03-11 The Trustees Of The University Of Pennsylvania Modulation of Regulatory T Cells by Human IL-18
JP2010503630A (ja) * 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー HMGB1のBox−AおよびHMGB1のBox−A変異体のポリマー複合体
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
EP2185188B1 (de) 2007-08-22 2014-08-06 Medarex, L.L.C. Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
US8168165B2 (en) 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. Cadm1に特異的な完全ヒト抗体
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
CN102507824B (zh) * 2011-11-01 2013-10-09 北京三元基因工程有限公司 聚乙二醇修饰蛋白质的修饰位点分析方法
PL2814829T3 (pl) 2012-02-13 2017-06-30 Bristol-Myers Squibb Company Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
EP2986306A4 (de) 2013-04-18 2016-12-07 Armo Biosciences Inc Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3206713A4 (de) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15-zusammensetzungen und verwendungen davon
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
JP7795181B2 (ja) * 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
US12564632B2 (en) 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN111378026A (zh) * 2018-12-27 2020-07-07 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法
JP7686563B2 (ja) * 2019-02-08 2025-06-02 ルブリゾル アドバンスド マテリアルズ, インコーポレイテッド 皮膚、毛髪、爪および/または粘膜の処置および/またはケアに有用な化合物
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
WO2021141986A1 (en) * 2020-01-07 2021-07-15 St. Jude Children's Research Hospital, Inc. Chimeric gmcsf-il18 receptor
CN116368148A (zh) * 2020-08-19 2023-06-30 明峰治疗股份公司 修饰的il-18多肽及其用途
KR20230117120A (ko) * 2020-11-02 2023-08-07 심카 아이엘-18, 인크. 인터류킨-18 변이체 및 사용 방법
CN116848130A (zh) * 2021-02-10 2023-10-03 国立大学法人长崎大学 新型人白细胞介素-18突变体及其用途
EP4067375A1 (de) * 2021-03-30 2022-10-05 Universität Ulm Fibrillenformende peptide
JP7849832B2 (ja) 2021-08-06 2026-04-22 国立大学法人 長崎大学 がんの治療剤
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
WO2023161853A1 (en) * 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
CA3244053A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag MODIFIED IL-18 POLYPEPTIDES
AU2023226512A1 (en) * 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
EP4584287A1 (de) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Il-18-polypeptidvarianten
US20240182536A1 (en) * 2022-11-11 2024-06-06 Mural Oncology, Inc. Interleukin 18 variants
CN116083572A (zh) * 2022-11-25 2023-05-09 广州希灵生物科技有限公司 一种检测il18基因启动子甲基化生物标志物的引物的应用
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250186597A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025041095A2 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Il-18 polypeptides modified with polymers
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof
US20250282776A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Bicyclic TLR7 Agonists and Uses Thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026069134A1 (en) 2024-09-26 2026-04-02 Bright Peak Therapeutics Ag Human therapy with il-18 immunocytokines
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US604630A (en) 1898-05-24 Avilliam
CS173849B1 (de) 1974-04-25 1977-03-31
US4436543A (en) 1982-06-03 1984-03-13 Kasten Harold B Neck ring mold apparatus for glass bottle manufacture
US4487325A (en) 1982-07-06 1984-12-11 Owens-Illinois, Inc. Crown closures and containers
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1676992A (en) 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5919758A (en) 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5747446A (en) 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP1669454A3 (de) 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomische DNS, die für ein Polypeptid kodiert, welches die Fähigkeit besitzt, die Interferon-Gamma Herstellung zu induzieren
JPH1080270A (ja) 1996-07-19 1998-03-31 Hayashibara Biochem Lab Inc ポリペプチドをプロセッシングする酵素
TW515843B (en) 1996-07-25 2003-01-01 Hayashibara Biochem Lab Process for producing an active polypeptide inducing interferon-γ production
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US5851798A (en) 1997-01-27 1998-12-22 Smithkline Beecham Corporation Nucleic acid encoding human GPR14 receptor
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AU775937B2 (en) 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
PL208592B1 (pl) 2000-06-15 2011-05-31 Smithkline Beecham Corp Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
ES2432967T3 (es) 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Derivados del Factor VII de coagulación
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7253260B2 (en) * 2002-04-17 2007-08-07 Smithkline Beecham Corporation Human IL-18 crystal structure
WO2004019866A2 (en) * 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
GB0323968D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions

Also Published As

Publication number Publication date
EP1613274B1 (de) 2010-03-03
US7311902B2 (en) 2007-12-25
EP1613274A4 (de) 2008-04-16
EP2261244A2 (de) 2010-12-15
EP1613274A2 (de) 2006-01-11
JP2007526207A (ja) 2007-09-13
WO2004091517A3 (en) 2006-07-27
TW200510454A (en) 2005-03-16
DE602004025799D1 (de) 2010-04-15
JP2011105737A (ja) 2011-06-02
JP4753867B2 (ja) 2011-08-24
EP2261244A3 (de) 2011-02-23
US20050008615A1 (en) 2005-01-13
ES2340494T3 (es) 2010-06-04
US20080206189A1 (en) 2008-08-28
US7736639B2 (en) 2010-06-15
AR044024A1 (es) 2005-08-24
WO2004091517A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
DE602004025799D1 (de) Humane il-18 substitutionsmutanten und deren konjugate
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
DE60316737D1 (de) Parallelstangenmechanismus und damit versehenes künstliches Gelenk
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
MA29079B1 (fr) Fusions et conjugues medicamenteux
EP1718667A4 (de) Heterocyclische, selbstopfernde linker und konjugate
DE60331861D1 (de) Ultraschallverfahren und ultraschallgerät
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
DE60138102D1 (de) Antikörper gegen menschliches mcp-1
FR2854158B1 (fr) Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2864080B1 (fr) Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
IS8074A (is) Setin 1,4- Díazepín og notkun theirra
DE502004004173D1 (de) Silber-legierung und deren Verwendung
FR2854633B1 (fr) Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
FR2882054B1 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
EP1646388A4 (de) Zytotoxische indeno- und isoindoloisochinolone
DE602004008668D1 (de) Benzoxazinderivate und deren verwendungen
DE602004016877D1 (de) Untersuchungsstuhl
DE10338270B4 (de) Variator und Variatoranordnung
DE602004002571D1 (de) Spektrophotometer und dessen baugruppen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties